THIRD QUARTER IN BRIEF
- Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (
July 31 ) - Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (
September 11 ) - Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech’s website (
September 13 )
EVENTS AFTER THE END OF THE PERIOD
- Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023 (
November 2 ) - The board of directors resolved on
November 9 , based on the authorization from the general meeting, to carry out a rights issue of approximatelySEK 51 million (before issue costs) to secure financing of the ongoing and planned development programs for tasquinimod and laquinimod
FINANCIAL SUMMARY
SEK M | Jul-Sep | Jan-Sep | Full year | ||
2023 2022 | 2023 2022 | 2022 | |||
Net sales | - | - | - | - | - |
Operating profit/loss | -10.6 | -13.4 | -33.7 | -42.6 | -57.9 |
Profit/loss after tax | -10.6 | -13.4 | -33.3 | -43.4 | -58.4 |
Earnings per share (SEK) | -0.04 | -0.06 | -0.13 | -0.19 | -0.25 |
Cash and cash equivalents (at close of period) | 5.6 | 55.0 | 41.8 |
The report is also available at www.activebiotech.com
© Modular Finance, source